CrystalGenomics to Present at J.P. Morgan Healthcare Conference on January 12
Pangyo, Korea, South, January 11, 2012 --(PR.com)-- CrystalGenomics, Inc. (KOSDAQ: CRYSTAL (083790)), a clinical stage biopharmaceutical company headquartered in Korea, has just announced that Joong Myung Cho, Ph.D., President & CEO, will present an overview of CrystalGenomics’ business strategy and an update on its development pipeline on Thursday, January 12, 2012 at 1:30 p.m. PST (4:30 p.m. EST), at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation will be a part of the Asia Track which will showcase corporate presentations from Asian healthcare companies. The presentation will provide a brief overview of CrystalGenomics and its clinical stage drug candidates including a novel mechanism anti-inflammatory product (CG100649) for osteoarthritis with potentially enhanced safety and efficacy profiles over existing drugs and a novel targeted first-in-class antibiotic candidate (CG400549) for MRSA infection.
Dr. Cho said, “We are quite honored to be selected by J.P. Morgan as one of the presenting companies. The time is ripe for us to increase CrystalGenomics’ visibility on a global level as we are on the brink of an important milestone of completion of phase 2b study for CG100649, which will reveal for the first time in its development history, its efficacy in direct comparison against Pfizer’s Celebrex®, a multi-billion dollar blockbuster drug.” He added that, “One of our goals from this presentation is to increase the awareness of CrystalGenomics and its therapeutic programs among the various global communities of industry leaders, potential partners, and investors.”
About CrystalGenomics
CrystalGenomics Inc. is a clinical stage biopharmaceutical company with drug discovery and development capabilities, headquartered in Seoul, Korea with a US presence for multi-national clinical management (CG Pharmaceuticals, Inc.) in Emeryville, California and publicly traded on the KOSDAQ exchange. CrystalGenomics is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in areas of infectious disease, cancer, and inflammatory diseases. The Company’s capabilities have been validated through prestigious publications including a cover page on Nature for being the first one to decipher a platform technology (2003), R&D collaborations with prominent pharmaceutical companies including AstraZeneca (2010), and a joint venture deal with ProQuest Investments involving an early stage asset (2008).
The Company’s lead development candidate is a next generation NSAID, CG100649 with a novel mechanism of suppressing COX-2 as well as carbonic anhydrase enzymes for improved cardiovascular, gastrointestinal, and renal safety profiles which is in Phase 2b development for osteoarthritis. Additionally, its novel HDAC inhibitor, CG200745 for solid tumors is in Phase 1, and its novel antibiotic candidate, CG400549 for MRSA infection, is undergoing preparation for Phase 2a Study initiation in the US. For more information on CrystalGenomics, please visit: www.cgxinc.com.
###
The presentation will be a part of the Asia Track which will showcase corporate presentations from Asian healthcare companies. The presentation will provide a brief overview of CrystalGenomics and its clinical stage drug candidates including a novel mechanism anti-inflammatory product (CG100649) for osteoarthritis with potentially enhanced safety and efficacy profiles over existing drugs and a novel targeted first-in-class antibiotic candidate (CG400549) for MRSA infection.
Dr. Cho said, “We are quite honored to be selected by J.P. Morgan as one of the presenting companies. The time is ripe for us to increase CrystalGenomics’ visibility on a global level as we are on the brink of an important milestone of completion of phase 2b study for CG100649, which will reveal for the first time in its development history, its efficacy in direct comparison against Pfizer’s Celebrex®, a multi-billion dollar blockbuster drug.” He added that, “One of our goals from this presentation is to increase the awareness of CrystalGenomics and its therapeutic programs among the various global communities of industry leaders, potential partners, and investors.”
About CrystalGenomics
CrystalGenomics Inc. is a clinical stage biopharmaceutical company with drug discovery and development capabilities, headquartered in Seoul, Korea with a US presence for multi-national clinical management (CG Pharmaceuticals, Inc.) in Emeryville, California and publicly traded on the KOSDAQ exchange. CrystalGenomics is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in areas of infectious disease, cancer, and inflammatory diseases. The Company’s capabilities have been validated through prestigious publications including a cover page on Nature for being the first one to decipher a platform technology (2003), R&D collaborations with prominent pharmaceutical companies including AstraZeneca (2010), and a joint venture deal with ProQuest Investments involving an early stage asset (2008).
The Company’s lead development candidate is a next generation NSAID, CG100649 with a novel mechanism of suppressing COX-2 as well as carbonic anhydrase enzymes for improved cardiovascular, gastrointestinal, and renal safety profiles which is in Phase 2b development for osteoarthritis. Additionally, its novel HDAC inhibitor, CG200745 for solid tumors is in Phase 1, and its novel antibiotic candidate, CG400549 for MRSA infection, is undergoing preparation for Phase 2a Study initiation in the US. For more information on CrystalGenomics, please visit: www.cgxinc.com.
###
Contact
CrystalGenomics, Inc.
Steven Kim
+82-31-628-2720
www.cgxinc.com
Steven Kim
+82-31-628-2720
www.cgxinc.com
Contact
Categories